D. Western Therapeutics Institute, Inc. (TYO:4576)

Japan flag Japan · Delayed Price · Currency is JPY
71.00
-2.00 (-2.74%)
Jun 3, 2026, 3:30 PM JST
Market Cap4.16B -9.9%
Revenue (ttm)305.24M -34.1%
Net Income-651.83M
EPS-12.90
Shares Out 56.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume352,200
Open72.00
Previous Close73.00
Day's Range71.00 - 72.00
52-Week Range71.00 - 181.00
Beta-0.01
Analystsn/a
Price Targetn/a
Earnings DateMay 14, 2026

About TYO:4576

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 19
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4576
Full Company Profile

Financial Performance

In 2025, TYO:4576's revenue was 387.00 million, a decrease of -17.83% compared to the previous year's 471.00 million. Losses were -632.00 million, -51.01% less than in 2024.

Financial Statements